Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057083 | 0.98 | ELANE (0.47) | ELANEKDM1ADGAT1MTNR1AMTNR1B | |
| SCHEMBL2223556 | 0.85 | ELANE (0.52) | ELANEKDM1ADGAT1HDAC1HDAC2 | |
| SCHEMBL22909379 | 0.80 | ELANE (0.33) | ELANE | |
| SCHEMBL17761153 | 0.80 | ELANE (0.32) | ELANEDGAT1CTSS | |
| SCHEMBL34317 | 0.80 | CA1 (0.36) | CA2 | |
| SCHEMBL20758462 | 0.79 | ELANE (0.33) | ELANE | |
| SCHEMBL1791670 | 0.78 | ELANE (0.43) | ELANEKDM1AMTNR1AMTNR1BCA2 | |
| SCHEMBL17474467 | 0.77 | ELANE (0.42) | ELANE | |
| SCHEMBL16932538 | 0.75 | CA1 (0.33) | CA2 | |
| SCHEMBL17751907 | 0.75 | MTNR1A (0.35) | DGAT1CTSSMTNR1AMTNR1BCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1498978-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | UBE INDUSTRIES (JP) | 2010-09-08 | — | — | EP | claimed |
| US-7297442-B2 | Nonaqueous electrolytic solution and lithium secondary battery employing the same | UBE INDUSTRIES, LTD. (JP) | 2007-11-20 | — | — | US | claimed |
| US-20050255384-A1 | Nonaqueous electrolytic solution and lithium secondary battery employing the same | UBE INDUSTRIES, LTD (JP) | 2005-11-17 | — | — | US | claimed |
| EP-1498978-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | Ube Industries, Ltd. (JP) | 2005-01-19 | — | — | EP | claimed |
| US-20250355350-A1 | NEGATIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING PROCESS, METHOD FOR FORMING CURED COATING, INTERLAYER INSULATING FILM, SURFACE PROTECTING FILM, AND ELECTRONIC COMPONENT | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-11-20 | — | — | US | disclosed |
| EP-4650874-A1 | NEGATIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING PROCESS, METHOD FOR FORMING CURED COATING, INTERLAYER INSULATING FILM, SURFACE PROTECTING FILM, AND ELECTRONIC COMPONENT | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-11-19 | — | — | EP | disclosed |
| CN-113150108-B | Solid-phase synthesis method of liraglutide | 台州吉诺生物科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
| EP-2850062-B1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH PATHOLOGICAL THROMBUS FORMATION | SANOFI SA (FR) | 2017-07-19 | — | — | EP | disclosed |
| EP-2882715-B1 | PYRAZOLE DERIVATIVES AND THEIR USE AS LPAR5 ANTAGONISTS | SANOFI SA (FR) | 2016-11-09 | — | — | EP | disclosed |
| US-9346762-B2 | Pyrazole derivatives and their use as LPAR5 antagonists | SANOFI (FR) | 2016-05-24 | — | — | US | disclosed |
| US-9346757-B2 | Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation | SANOFI (FR) | 2016-05-24 | — | — | US | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
| US-7297442-B2 | Nonaqueous electrolytic solution and lithium secondary battery employing the same | UBE INDUSTRIES, LTD. (JP) | 2007-11-20 | — | — | US | disclosed |
| US-7261975-B2 | Performance such as cycle characteristics, electric capacity, and storage characteristics | UBE INDUSTRIES, LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20070054185-A1 | Performance such as cycle characteristics, electric capacity, and storage characteristics | UBE INDUSTRIES, LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1672729-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | Ube Industries, Ltd. (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-20050255384-A1 | Nonaqueous electrolytic solution and lithium secondary battery employing the same | UBE INDUSTRIES, LTD (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1498978-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | Ube Industries, Ltd. (JP) | 2005-01-19 | — | — | EP | disclosed |
| US-4254273-A | INTERMEDIATES FOR HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330798-A1 | TREATMENT OF INFECTIONS | H1-10, PM20D2, ELANE | ELANE 3/4885KDM1A 1816/4885DGAT1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.